Robert Lechleider compensation by year
Immunome Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $530,300 |
| Stock awards | $0 |
| Option awards | $1,897,525 |
| Non-equity incentive | $307,600 |
| Pension and deferred compensation | $0 |
| All other | $12,193 |
| Total | $2,747,618 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunome Inc. DEF 14A filed April 24, 2026, accession 0001140361-26-016685, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Immunome Inc. filed document, accession 0001140361-26-016685. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 183,334 | — | $8.73 |
| Option | 133,334 | — | $12.92 |
| Option | 242,000 | — | $10.60 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immunome Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2025 proxy (filed April 24, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-23 | Grant or award derivative | — | 108,000 | $0.00 | 108,000 |
| 2026-07-23 | Grant or award | — | 54,000 | $0.00 | 69,805 |
| 2026-07-02 | Exercise or conversion derivative | 10b5-1 | 55,000 | $0.00 | 290,000 |
| 2026-07-02 | Sale | 10b5-1 | 22,714 | $21.95 | 48,091 |
| 2026-07-02 | Sale | 10b5-1 | 16,214 | $22.76 | 31,877 |
| 2026-07-02 | Exercise or conversion | 10b5-1 | 55,000 | $8.73 | 70,805 |
| 2026-07-02 | Sale | 10b5-1 | 16,072 | $23.44 | 15,805 |
| 2026-06-25 | Exercise or conversion | 10b5-1 | 55,000 | $8.73 | 70,805 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Immunome’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Clay Siegall | President, Chief Executive Officer and Chairman of the Board | $7,682,601 |
| Max Rosett | Chief Financial Officer | $2,785,557 |
| Robert Lechleider · this page | Chief Medical Officer | $2,747,618 |
Robert Lechleider's compensation dossier, Immunome
You have read Robert Lechleider's totals and holdings. The dossier adds each equity grant Immunome disclosed for Robert Lechleider and Immunome's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Immunome compensation record
free company briefThis page is one person within Immunome's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immunome's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunome's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order IMNM
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.